Suzhou Fengbei Biotech announced that in order to cope with changes in the foreign exchange market and prevent risks, the company and its subsidiaries plan to carry out foreign exchange derivatives transactions such as forward settlement. The types of transactions include forward foreign exchange settlements, foreign exchange options, etc., and the counterparty is a qualified financial institution. It is estimated that no more than 50 million US dollars of idle own funds will be used to conduct business, the period will not exceed 12 months, the transaction amount can be recycled, and the maximum transaction margin and premium will not exceed 2.5 million US dollars. The company formulates corresponding risk control measures, stating that business development is necessary and feasible.

Suzhou Fengbei Biotech announced that in order to cope with changes in the foreign exchange market and prevent risks, the company and its subsidiaries plan to carry out foreign exchange derivatives transactions such as forward settlement. The types of transactions include forward foreign exchange settlements, foreign exchange options, etc., and the counterparty is a qualified financial institution. It is estimated that no more than 50 million US dollars of idle own funds will be used to conduct business, the period will not exceed 12 months, the transaction amount can be recycled, and the maximum transaction margin and premium will not exceed 2.5 million US dollars. The company formulates corresponding risk control measures, stating that business development is necessary and feasible.